COMMUNIQUÉS West-GlobeNewswire

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
18/05/2026
New analysis from the IMPACT-TD Registry confirms tardive dyskinesia (TD) causes a significant burden for most individuals with concomitant mood disorders, impacting their lives regardless of age The data shows that 85 [...]
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
18/05/2026
MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders [...]
Aradigm Brings Cell and Gene Therapy Benefits Platform to Quantum Health’s Customers
18/05/2026
Collaboration will help employers manage catastrophic financial risk while ensuring access to life-changing treatments NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Aradigm , the market’s first comprehensive, transparent [...]
Arvinas Employees Give Back During Company-wide Impact Day
18/05/2026
NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that [...]
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
18/05/2026
HOUSTON, May 18, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development of therapeutics [...]
Parexel Launches ParexelAI™, Delivering AI Innovation to Accelerate Clinical Development
18/05/2026
Innovative, proprietary suite of artificial intelligence services and capabilities deliver proven speed, quality and efficiency results for sponsors and patients RALEIGH, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Parexel, [...]
Alpha Tau to Participate in May Investor Conferences
18/05/2026
JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced [...]
Philips introduces SmartIQ to address the trade-off between image quality and radiation dose in coronary procedures
18/05/2026
May 18, 2026 Greater differentiation of clinical details through contrast-rich images with reduced background noise For coronary procedures, a new ultra-low dose protocol employs over 50% less X-ray radiation dose [1] [...]
Red Ribbon Recovery Indiana reports strong patient outcomes in first year of operation
18/05/2026
New Indiana rehab reports 88% sobriety at 30 days — and 70% at six months Greenwood, Indiana, May 18, 2026 (GLOBE NEWSWIRE) -- Red Ribbon Recovery Indiana, which marks its first year of operation this June, is releasing [...]
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
18/05/2026
New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients completing the ongoing Halneuron ® 4-week [...]
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
18/05/2026
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000 [...]
Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
18/05/2026
THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease
18/05/2026
Last Patient Evaluation Visit Completed with Topline Data Release Targeted Q3-2026 CARSON CITY, Nev., May 18, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company [...]
Arbor Biotechnologies Appoints Mathew Pletcher, Ph.D., as Chief Scientific Officer
18/05/2026
Gene therapy and rare disease leader with nearly two decades of drug development experience to focus on advancing the company’s next-generation gene editing pipeline CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- [...]
New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA’s Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo
18/05/2026
Multicenter prospective RCT published in JAAD confirms superiority of XTRAC® Excimer Laser plus oral JAK inhibitors over tacrolimus combination therapy in children aged 2–18 years with progressive vitiligo, fueling [...]
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
18/05/2026
COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to [...]
UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
18/05/2026
Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD [...]
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
18/05/2026
TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to [...]
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
18/05/2026
Vancouver, Canada, May 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]

Pages